Skip to content
Catalyst

Momordica charantiaFinding

Momordica charantia decreases fasting blood glucose

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“Patients receiving adjunctive Momordica charantia supplementation demonstrated a significantly greater reduction in HbA1c and fasting plasma glucose compared with patients continuing dual antidiabetic therapy alone.”
Quoted verbatim from Phytotherapeutic Supplementation with Momordica charantia: Beneficial Effects in Patients with Suboptimal Glycemic Control on Double Antidiabetic Therapy-A Real-World Evidence Observational Study.
This finding among the 111 findings on its endpoint

Momordica charantia

Fasting blood glucose

lowers

Who
Adults with type 2 diabetes on metformin plus dapagliflozin 10 mg/day for 6 months who still had HbA1c of 6.5% or more; compared over months 6 to 9 with patients who had reached HbA1c below 6.5% and continued dual therapy alone
Dose studied
450 mg three times daily after meals, for 3 months, added to metformin and dapagliflozin

Moderate evidencePMID 41599921 · 2026

02 · The study

Study
cohort
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Nutrients
What else it reported2 findings · 0 compounds · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZD8R343FG5BBJZ6P6M2GVS